Business Description
ITeos Therapeutics Inc
NAICS : 541714
SIC : 2833
ISIN : US46565G1040
Share Class Description:
ITOS: Ordinary SharesDescription
ITeos Therapeutics Inc is a biopharmaceutical company. It designs novel product candidates with optimized pharmacologic properties to improve clinical outcomes by restoring the immune response against cancer. The company's product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist, EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody among other drug candidates.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 87.8 | |||||
| Equity-to-Asset | 0.86 | |||||
| Debt-to-Equity | 0.01 | |||||
| Debt-to-EBITDA | -0.04 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | 3.07 | |||||
| Beneish M-Score | 43.84 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -16.1 | |||||
| 3-Year EPS without NRI Growth Rate | -3 | |||||
| 3-Year FCF Growth Rate | -20.8 | |||||
| 3-Year Book Growth Rate | 20.3 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 25.27 | |||||
| 9-Day RSI | 32.97 | |||||
| 14-Day RSI | 39.36 | |||||
| 6-1 Month Momentum % | 22.73 | |||||
| 12-1 Month Momentum % | -22.75 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 13.76 | |||||
| Quick Ratio | 13.76 | |||||
| Cash Ratio | 13.29 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -0.7 | |||||
| Shareholder Yield % | -0.19 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -1149.37 | |||||
| Net Margin % | -894.35 | |||||
| FCF Margin % | -847.34 | |||||
| ROE % | -18.09 | |||||
| ROA % | -15.94 | |||||
| ROIC % | -140.71 | |||||
| ROC (Joel Greenblatt) % | -1746.45 | |||||
| ROCE % | -21.51 | |||||
| Years of Profitability over Past 10-Year | 2 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 30.69 | |||||
| PB Ratio | 0.66 | |||||
| Price-to-Tangible-Book | 0.66 | |||||
| EV-to-EBIT | 1.07 | |||||
| EV-to-EBITDA | 1.07 | |||||
| EV-to-Revenue | -12.27 | |||||
| EV-to-Forward-Revenue | 3.81 | |||||
| EV-to-FCF | 1.45 | |||||
| Price-to-Net-Current-Asset-Value | 0.83 | |||||
| Price-to-Net-Cash | 0.86 | |||||
| Earnings Yield (Greenblatt) % | 93.46 | |||||
| FCF Yield % | -28.2 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:ITOS
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
ITeos Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 12.595 | ||
| EPS (TTM) ($) | -3.15 | ||
| Beta | 0.75 | ||
| Volatility % | 50.08 | ||
| 14-Day RSI | 39.36 | ||
| 14-Day ATR ($) | 0.622762 | ||
| 20-Day SMA ($) | 12.06 | ||
| 12-1 Month Momentum % | -22.75 | ||
| 52-Week Range ($) | 8.2 - 18.24 | ||
| Shares Outstanding (Mil) | 35.84 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
ITeos Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
ITeos Therapeutics Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
ITeos Therapeutics Inc Frequently Asked Questions
What is ITeos Therapeutics Inc(ITOS)'s stock price today?
The current price of ITOS is $10.56. The 52 week high of ITOS is $18.24 and 52 week low is $8.20.
When is next earnings date of ITeos Therapeutics Inc(ITOS)?
The next earnings date of ITeos Therapeutics Inc(ITOS) is 2024-05-10 Est..
Does ITeos Therapeutics Inc(ITOS) pay dividends? If so, how much?
ITeos Therapeutics Inc(ITOS) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers